$84.85-3.27 (-3.71%)
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally.
Integer Holdings Corporation in the Healthcare sector is trading at $84.85. The stock is currently 31% below its 52-week high of $123.78, remaining 4.0% below its 200-day moving average. Technical signals show neutral RSI of 48 and bullish MACD crossover, explaining why ITGR maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structura...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Integer (NYSE:ITGR) reported first-quarter 2026 results that management said were in line with the outlook it provided in February, while also lowering its full-year forecast to reflect updated customer forecasts and additional risk adjustments across its portfolio. The company also disclosed that i
Integer's shares jump despite a Q1 EPS miss and margin pressure, as revenues rise slightly Y/Y and beat estimates on strength across key product lines.
Moby summary of Integer Holdings Corporation's Q1 2026 earnings call
Medical technology company Integer Holdings (NYSE:ITGR) reported Q1 CY2026 results topping the market’s revenue expectations, but sales were flat year on year at $439.6 million. On the other hand, the company’s full-year revenue guidance of $1.82 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $1.20 per share was 1.1% above analysts’ consensus estimates.